 Jason Hoppe
Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 37 | 2025 | 2046 | 4.170 |
Why?
| | Analgesics, Opioid | 23 | 2024 | 992 | 4.170 |
Why?
| | Buprenorphine | 9 | 2025 | 169 | 3.280 |
Why?
| | Decision Support Systems, Clinical | 7 | 2025 | 223 | 3.160 |
Why?
| | Opioid-Related Disorders | 12 | 2025 | 509 | 3.060 |
Why?
| | Prescription Drug Monitoring Programs | 6 | 2023 | 14 | 2.970 |
Why?
| | Narcotic Antagonists | 10 | 2025 | 179 | 1.890 |
Why?
| | Opiate Substitution Treatment | 8 | 2025 | 151 | 1.780 |
Why?
| | Practice Patterns, Physicians' | 14 | 2023 | 1301 | 1.680 |
Why?
| | Naloxone | 3 | 2024 | 121 | 1.610 |
Why?
| | Back Pain | 4 | 2023 | 50 | 1.360 |
Why?
| | Pain | 4 | 2023 | 754 | 1.060 |
Why?
| | Prescription Drugs | 5 | 2017 | 109 | 1.040 |
Why?
| | Electronic Health Records | 5 | 2025 | 1046 | 0.940 |
Why?
| | Emergency Medicine | 3 | 2024 | 226 | 0.780 |
Why?
| | Drug Overdose | 5 | 2021 | 345 | 0.730 |
Why?
| | Length of Stay | 3 | 2024 | 1205 | 0.640 |
Why?
| | Pain Management | 3 | 2017 | 347 | 0.530 |
Why?
| | Drug Prescriptions | 4 | 2023 | 243 | 0.520 |
Why?
| | Attitude of Health Personnel | 4 | 2024 | 1163 | 0.510 |
Why?
| | Drug Monitoring | 2 | 2017 | 218 | 0.490 |
Why?
| | Controlled Substances | 1 | 2014 | 1 | 0.460 |
Why?
| | Physicians | 3 | 2024 | 907 | 0.460 |
Why?
| | Substance Abuse Detection | 2 | 2014 | 87 | 0.440 |
Why?
| | Humans | 49 | 2025 | 136769 | 0.440 |
Why?
| | Pharmacies | 1 | 2014 | 38 | 0.440 |
Why?
| | Adult | 24 | 2025 | 37631 | 0.420 |
Why?
| | Prescriptions | 2 | 2023 | 67 | 0.420 |
Why?
| | Drug-Seeking Behavior | 1 | 2013 | 22 | 0.410 |
Why?
| | Retrospective Studies | 16 | 2024 | 15504 | 0.390 |
Why?
| | Pharmacists | 1 | 2014 | 261 | 0.370 |
Why?
| | Middle Aged | 17 | 2025 | 33228 | 0.370 |
Why?
| | Cannabinoids | 3 | 2020 | 161 | 0.360 |
Why?
| | Male | 27 | 2025 | 67313 | 0.340 |
Why?
| | Patient Discharge | 1 | 2016 | 894 | 0.320 |
Why?
| | Female | 25 | 2025 | 72796 | 0.310 |
Why?
| | Abdominal Pain | 3 | 2019 | 145 | 0.280 |
Why?
| | Drug Packaging | 2 | 2017 | 45 | 0.260 |
Why?
| | Marijuana Abuse | 2 | 2020 | 232 | 0.260 |
Why?
| | Cross-Sectional Studies | 8 | 2021 | 5423 | 0.230 |
Why?
| | Academic Medical Centers | 2 | 2017 | 504 | 0.210 |
Why?
| | Vomiting | 3 | 2020 | 130 | 0.210 |
Why?
| | Delivery of Health Care | 2 | 2021 | 934 | 0.210 |
Why?
| | Capsaicin | 2 | 2020 | 26 | 0.200 |
Why?
| | Benzodiazepines | 3 | 2023 | 153 | 0.190 |
Why?
| | Prescription Drug Misuse | 1 | 2022 | 40 | 0.180 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 178 | 0.180 |
Why?
| | Quality Indicators, Health Care | 1 | 2023 | 307 | 0.170 |
Why?
| | Young Adult | 8 | 2019 | 13129 | 0.170 |
Why?
| | Certification | 1 | 2020 | 103 | 0.160 |
Why?
| | Patient Handoff | 1 | 2020 | 32 | 0.160 |
Why?
| | Ketorolac | 1 | 2019 | 20 | 0.150 |
Why?
| | Haloperidol | 1 | 2019 | 34 | 0.150 |
Why?
| | Antiemetics | 1 | 2019 | 43 | 0.150 |
Why?
| | Drug Storage | 2 | 2017 | 57 | 0.150 |
Why?
| | Infection Control | 1 | 2020 | 166 | 0.150 |
Why?
| | Social Work | 1 | 2020 | 85 | 0.150 |
Why?
| | Poisoning | 2 | 2017 | 116 | 0.150 |
Why?
| | Qualitative Research | 2 | 2024 | 1366 | 0.150 |
Why?
| | Automobile Driving | 1 | 2020 | 148 | 0.140 |
Why?
| | Risk Factors | 4 | 2023 | 10326 | 0.140 |
Why?
| | United States | 7 | 2021 | 14690 | 0.140 |
Why?
| | Acetaminophen | 2 | 2011 | 266 | 0.140 |
Why?
| | Quality Improvement | 2 | 2024 | 1163 | 0.140 |
Why?
| | Referral and Consultation | 2 | 2021 | 780 | 0.140 |
Why?
| | Accidents, Home | 1 | 2017 | 31 | 0.130 |
Why?
| | Medical Staff, Hospital | 1 | 2017 | 83 | 0.130 |
Why?
| | Alcoholism | 1 | 2023 | 804 | 0.130 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 350 | 0.120 |
Why?
| | Marijuana Smoking | 1 | 2019 | 249 | 0.120 |
Why?
| | Logistic Models | 3 | 2017 | 2067 | 0.120 |
Why?
| | Pharmacovigilance | 1 | 2015 | 23 | 0.120 |
Why?
| | Drug Utilization | 2 | 2014 | 169 | 0.120 |
Why?
| | Inappropriate Prescribing | 1 | 2016 | 55 | 0.120 |
Why?
| | Odds Ratio | 2 | 2017 | 1065 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.120 |
Why?
| | Codeine | 1 | 2015 | 6 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 358 | 0.120 |
Why?
| | Hydrocodone | 1 | 2015 | 17 | 0.120 |
Why?
| | Pandemics | 2 | 2021 | 1612 | 0.120 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 77 | 0.120 |
Why?
| | Guideline Adherence | 2 | 2017 | 546 | 0.120 |
Why?
| | Medication Reconciliation | 1 | 2015 | 29 | 0.120 |
Why?
| | Medication Errors | 1 | 2015 | 95 | 0.120 |
Why?
| | Cohort Studies | 2 | 2016 | 5701 | 0.110 |
Why?
| | Oxycodone | 1 | 2015 | 42 | 0.110 |
Why?
| | Prospective Studies | 3 | 2023 | 7572 | 0.110 |
Why?
| | Self Report | 2 | 2020 | 822 | 0.110 |
Why?
| | Urban Population | 1 | 2017 | 476 | 0.110 |
Why?
| | Aged | 8 | 2020 | 23794 | 0.110 |
Why?
| | Indazoles | 1 | 2014 | 69 | 0.100 |
Why?
| | Health Services Accessibility | 1 | 2021 | 977 | 0.100 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 250 | 0.100 |
Why?
| | Antipsychotic Agents | 2 | 2019 | 193 | 0.100 |
Why?
| | Respiratory Insufficiency | 1 | 2016 | 317 | 0.100 |
Why?
| | Chronic Pain | 1 | 2016 | 259 | 0.100 |
Why?
| | Adolescent | 6 | 2019 | 21384 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2019 | 7585 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 481 | 0.090 |
Why?
| | Cooperative Behavior | 1 | 2014 | 445 | 0.090 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 12 | 0.090 |
Why?
| | Colorado | 3 | 2019 | 4516 | 0.090 |
Why?
| | Hospitalization | 1 | 2020 | 2183 | 0.090 |
Why?
| | Fractures, Bone | 1 | 2015 | 376 | 0.080 |
Why?
| | Curriculum | 1 | 2016 | 976 | 0.080 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2011 | 124 | 0.080 |
Why?
| | Acetylcysteine | 1 | 2010 | 145 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1571 | 0.080 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 90 | 0.070 |
Why?
| | Cardiovascular System | 1 | 2009 | 137 | 0.070 |
Why?
| | Antidotes | 1 | 2009 | 143 | 0.070 |
Why?
| | Prescription Drug Overuse | 2 | 2017 | 13 | 0.070 |
Why?
| | Consensus | 2 | 2021 | 678 | 0.060 |
Why?
| | Nausea | 2 | 2019 | 111 | 0.060 |
Why?
| | Medical History Taking | 2 | 2015 | 117 | 0.060 |
Why?
| | Nonprescription Drugs | 2 | 2015 | 63 | 0.050 |
Why?
| | Phenobarbital | 1 | 2023 | 19 | 0.050 |
Why?
| | Lorazepam | 1 | 2023 | 27 | 0.050 |
Why?
| | Interviews as Topic | 1 | 2024 | 772 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2019 | 3540 | 0.040 |
Why?
| | Wisconsin | 1 | 2020 | 100 | 0.040 |
Why?
| | Organizational Innovation | 1 | 2020 | 138 | 0.040 |
Why?
| | Administration, Topical | 1 | 2019 | 149 | 0.040 |
Why?
| | Community Health Workers | 1 | 2020 | 62 | 0.040 |
Why?
| | Data Collection | 1 | 2022 | 668 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 357 | 0.040 |
Why?
| | Risk Assessment | 2 | 2017 | 3432 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 266 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 281 | 0.030 |
Why?
| | Health Transition | 1 | 2016 | 7 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 159 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 530 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 5742 | 0.030 |
Why?
| | Plant Preparations | 1 | 2015 | 36 | 0.030 |
Why?
| | Child Behavior | 1 | 2017 | 246 | 0.030 |
Why?
| | Focus Groups | 1 | 2017 | 515 | 0.030 |
Why?
| | Analgesics | 1 | 2016 | 205 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2016 | 562 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2016 | 275 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 117 | 0.030 |
Why?
| | Vitamins | 1 | 2015 | 185 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 506 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2016 | 1316 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1507 | 0.020 |
Why?
| | Program Evaluation | 1 | 2016 | 889 | 0.020 |
Why?
| | Eating | 1 | 2014 | 379 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3265 | 0.020 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2015 | 559 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 38 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 387 | 0.020 |
Why?
| | Decision Making | 1 | 2017 | 898 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 207 | 0.020 |
Why?
| | Aging | 1 | 2020 | 1864 | 0.020 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 23 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3284 | 0.020 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 17 | 0.020 |
Why?
| | Aripiprazole | 1 | 2009 | 20 | 0.020 |
Why?
| | Risperidone | 1 | 2009 | 29 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 412 | 0.020 |
Why?
| | Thiazoles | 1 | 2009 | 123 | 0.020 |
Why?
| | Anaphylaxis | 1 | 2010 | 105 | 0.020 |
Why?
| | Safety | 1 | 2010 | 338 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 1062 | 0.020 |
Why?
| | Quinolones | 1 | 2009 | 137 | 0.020 |
Why?
| | Child | 2 | 2017 | 21822 | 0.020 |
Why?
| | Piperazines | 1 | 2009 | 350 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2052 | 0.020 |
Why?
| | Internship and Residency | 1 | 2016 | 1132 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2009 | 738 | 0.010 |
Why?
| | Infant | 1 | 2017 | 9397 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11000 | 0.010 |
Why?
| | Prognosis | 1 | 2011 | 4013 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2010 | 10745 | 0.010 |
Why?
|
|
Hoppe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|